Eisai and Lilly were the biggest winners at the 19^th Annual Scrip Awards in a glittering ceremony at the Dorchester in London’s Mayfair, hosted by the actor and comedian Jon Culshaw.

Survey shows long-term optimism but fears that 2024 will be another hard slog for those biotechs with dwindling cash resources.

Sonelokimab follows a mid-stage slam-dunk in hidradenitis suppurativa with a rather more equivocal result in a different immune condition in the ARGO study.

Despite its Phase III blow-up, Acelyrin is continuing to back izokibep in the skin disease. But other developers are trying immune agents old and new in what could turn into a billion-dollar market.